GH55 treatment for advanced cancers with specific mutations

A Phase I/II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of GH55 in Patients Harboring MAPK Pathway Mutations in Advanced Solid Tumors

This study is testing a new treatment called GH55 for people with advanced cancers that have specific mutations to see if it can help them when other treatments haven't worked.

Quick facts

• Phase: Phase1; Phase2
• Study type: Interventional
• Enrollment: 110 (estimated)
• Ages: 18 Years to 80 Years
• Sex: All
• Sponsor: Suzhou Genhouse Bio Co., Ltd. (Academic / other)
• Drugs / interventions: chemotherapy, immunotherapy, radiation
• Locations: 1 site (Shanghai, Shanghai Municipality)
• Trial ID: NCT06310382 on ClinicalTrials.gov

What this trial studies

This clinical trial evaluates the safety and efficacy of GH55 in patients with advanced solid tumors that have MAPK pathway mutations. It consists of two phases: a dose escalation phase I to determine the maximum tolerated dose (MTD) and a dose expansion phase II to further assess safety and efficacy. Participants will receive varying doses of GH55, and their responses will be monitored to gather pharmacokinetic (PK) and pharmacodynamic (PD) data. The study aims to provide insights into the potential benefits of GH55 for patients who have not responded to standard treatments.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18-80 with confirmed MAPK mutations in their advanced solid tumors who have failed standard treatments.

Not a fit: Patients with tumors that do not have MAPK mutations or those who are suitable for standard treatment may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could offer a new therapeutic option for patients with advanced cancers that currently have limited treatment options.

How similar studies have performed: While this approach is novel in its specific targeting of MAPK mutations with GH55, similar studies targeting other mutations have shown promising results.

Eligibility criteria

Inclusion Criteria:

Subjects must meet all the following inclusion criteria to be qualified for study enrollment:

1. Male or female subjects aged 18-80 years (inclusive).
2. Patients with histologically or cytologically confirmed MAPK mutant (presence of RAS/RAF/MEK/ERK mutations) locally advanced or metastatic solid tumors.
3. Patients who have failed standard treatment or have no standard treatment regimen or are not suitable for standard treatment currently.
4. Dose escalation: At least one assessable tumor lesion according to RECIST version 1.1; Dose expansion: At least one measurable tumor lesion according to RECIST version 1.1 (tumor lesion located in the region of previous radiotherapy or other locoregional treatment sites is usually not considered a measurable lesion, unless this lesion shows clear progression or persists for 3 months after radiotherapy).
5. Eastern Cooperative Oncology Group (ECOG) performance status score: Phase I dose escalation: 0-1. Phase II dose expansion: 0-2.
6. 3 months or longer expected survival.
7. Major organs are functioning normally, and laboratory tests meet the following criteria during the screening period.

Hematological system (has not received any blood transfusion or hematopoietic stimulating factor therapy within the past 14 days) Absolute neutrophil count (ANC) ≥ 1.5 × 109/L Platelet Count (PLT) ≥ 75 × 109/L Hemoglobin (Hb) ≥ 90 g/L Liver function Albumin (ALB) ≥ 3.0 g/dL Total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN) Liver metastasis or liver cancer patients: ≤ 2.5 × ULN Alanine Aminotransferase (ALT) ≤ 2.5 × ULN; Liver metastasis or liver cancer patients: ≤ 5 × ULN Aspartate aminotransferase (AST) ≤ 2.5 × ULN; Liver metastasis or liver cancer patients: ≤ 5 × ULN Renal function Creatinine clearance rate (Ccr) ≥ 60 mL/min (calculated based on the Cockcroft-Gault formula) Coagulation function Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN International normalized ratio (INR) ≤ 1.5 × ULN Cardiac function Left ventricular ejection fraction (LVEF) ≥ 50% QT interval corrected by the Fridericia formula (QTcF) Males \< 450 ms, Females \< 470 ms 7. Qualified patients (male and female) with childbearing potential must agree to use reliable contraceptives (hormone or barrier or abstinence) with their partners during the study and until at least 3 months after the last dose; female patients with childbearing potential must be negative for the blood pregnancy test within 1 week before the first dose.

8\. Subjects must give informed consent to the study and voluntarily signed the informed consent form prior to study initiation.

Exclusion Criteria:

Subjects who meet any one of the following exclusion criteria are not eligible for study enrollment:

1. Received antitumor therapy such as chemotherapy within 3 weeks before the first dose, radiotherapy, biotherapy, endocrine therapy, targeted therapy, and immunotherapy within 4 weeks before the first dose, except for the following:

   * Use of nitrosoureas or mitomycin C within 6 weeks prior to the first dose of the investigational drug;
   * Use of oral fluorouracil(s), small molecule targeted drugs, and antitumor traditional Chinese medicine within 2 weeks prior to the first dose of the investigational drug;
   * Local palliative radiotherapy within 2 weeks prior to the first dose of the investigational drug.
2. Received other unmarketed clinical investigational drug or therapy within 4 weeks prior to the first dose.
3. Underwent major organ surgery (excluding needle biopsy) or had significant trauma within 4 weeks prior to the first dose or requires selective surgery during the study period.
4. Use of strong CYP3A4 inhibitors or inducers within 1 week prior to the first dose of the investigational drug.
5. Previously received other selective ERK inhibitors.
6. Previously received allogeneic HSCT or organ transplantation.
7. Adverse drug reactions of previous antitumor treatment have not recovered to grade ≤ 1 as per CTCAE version 5.0 (except for toxicity without safety risk judged by the investigator, such as alopecia, grade 2 peripheral neurotoxicity, and hypothyroidism that is stable after hormone replacement therapy).
8. Brain parenchymal metastasis or meningeal metastasis with clinical symptoms unsuitable for study participation as judged by the investigator.
9. Patient with active infection and currently requires intravenous anti-infective therapy.
10. History of immunodeficiency, including being positive for HIV antibody test.
11. Active hepatitis B \[HBsAg positive and HBV-DNA \> 500 IU/mL or LLQ of the study site (when the LLQ is \> 500 IU/mL)\], for which antiviral therapies other than interferon are permitted; Active hepatitis C (patients who are positive for HCV antibody but whose HCV-RNA is \< study site LLQ can be included).
12. History of severe cardiovascular and cerebrovascular diseases, including but not limited to:

    * Severe abnormalities in cardiac rhythm or conduction, such as ventricular arrhythmia or second- or third-degree atrioventricular block requiring clinical intervention;
    * Acute coronary syndrome, congestive heart failure, aortic dissection, stroke or other grade 3 or greater cardiovascular and cerebrovascular events within 6 months prior to the first dose;
    * New York Heart Disease Association (NYHA) class ≥ III cardiac function or left ventricular ejection fraction (LVEF) \< 50%;
    * Clinically uncontrolled hypertension;
    * Any factors that increase the risk of QTc prolongation or arrhythmia, such as heart failure, hypokalemia that is difficult to correct, congenital long QT syndrome, family history of long QT syndrome, and use of concomitant medication known to prolong QT interval.
13. History of other malignant tumors (except for the cured squamous cell carcinoma in situ of the skin, basal cell carcinoma, and cervical carcinoma in situ that have not recurred within 5 years and are considered acceptable for study enrollment by the investigator; except for patients who are considered acceptable for enrollment by the investigator in the dose escalation study).
14. History of retinal vein occlusion or central serous retinopathy, or patients with clinically significant abnormalities in the ophthalmological examination during the screening period and judged by the investigator to be unsuitable for enrollment.
15. Unable to swallow medication or has conditions that severely impact gastrointestinal absorption (e.g. Chronic diarrhea or intestinal obstruction) as judged by the investigator.
16. Clinically uncontrolled third space effusion judged by the investigator to be unsuitable for enrollment.
17. Patients with current interstitial lung disease (except radiation-induced pulmonary fibrosis that does not required hormone therapy).
18. Known alcohol or drug dependence.
19. Mental disorder or poor compliance.
20. Previous history of severe allergy, or allergy to any active or non-active ingredients of the investigational drug.
21. Pregnant or lactating women.
22. Other conditions judged by the investigator that render the subject unsuitable for participation.

Where this trial is running

Shanghai, Shanghai Municipality

• Shanghai East Hospital — Shanghai, Shanghai Municipality, China (Recruiting)

Study contacts

• Principal investigator: Jin Li, Dpctorate — 021-38804518
• Study coordinator: YIMING ZHOU, bachelor

Conditions Advanced Solid Tumors With MAPK Signal Pathway Mutations